22nd Century Group (NASDAQ:XXII) focuses on biotechnology, striving to decrease the harm caused by smoking through its proprietary tobacco products that have reduced nicotine content. Additionally, the company works on hemp/cannabis research to develop new plant varieties with specific cannabinoid profiles. With a mission geared towards improving health and reducing the impacts of smoking, 22nd Century Group is dedicated to advancing agricultural biotechnology projects and bringing to market tobacco with potentially less addictive properties, alongside exploring the growing potentials of cannabis for various uses. This combination of objectives underscores their commitment to public health and innovation in plant science.